BioMarin Pharmaceutical (NASDAQ:BMRN) Issues Earnings Results, Beats Estimates By $0.21 EPS

Key Points

• BioMarin Pharmaceutical reported earnings of $1.25 per share for the quarter, exceeding analysts' expectations of $1.02, and updated its FY 2025 guidance to $4.400-4.550 EPS.
• Shares of BioMarin (NASDAQ:BMRN) increased by 3.7% to $60.31 following the earnings announcement, with significant trading volume of over 6 million shares.
• Analysts' price targets have fluctuated, with Citigroup lowering its target from $82 to $78, while JPMorgan raised its target from $108 to $113, reflecting a range of opinions among analysts on the company's stock potential.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported $1.23 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.21, Briefing.com reports. BioMarin Pharmaceutical had a return on equity of 11.34% and a net margin of 17.76%. The firm had revenue of $825.00 million for the quarter, compared to analysts' expectations of $761.51 million. During the same period in the prior year, the firm posted $0.55 earnings per share. The firm's quarterly revenue was up 15.9% on a year-over-year basis. BioMarin Pharmaceutical updated its FY 2025 guidance to 4.400-4.550 EPS.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $60.31 on Tuesday. The firm has a market capitalization of $11.57 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 0.80 and a beta of 0.18. The business's fifty day moving average price is $57.16 and its 200 day moving average price is $61.79. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.52 and a quick ratio of 3.49. BioMarin Pharmaceutical has a 12 month low of $52.93 and a 12 month high of $94.85.

Insider Buying and Selling

In related news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total value of $105,927.66. Following the transaction, the chief accounting officer owned 14,173 shares of the company's stock, valued at $840,600.63. This represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently bought and sold shares of the business. NewEdge Advisors LLC increased its holdings in BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock valued at $266,000 after buying an additional 388 shares during the last quarter. Focus Partners Wealth increased its holdings in BioMarin Pharmaceutical by 70.2% in the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company's stock valued at $835,000 after buying an additional 4,876 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in BioMarin Pharmaceutical by 207.4% in the first quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company's stock valued at $850,000 after buying an additional 8,112 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Wall Street Analysts Forecast Growth

BMRN has been the topic of a number of recent analyst reports. The Goldman Sachs Group decreased their price objective on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a report on Monday, May 5th. Wolfe Research set a $95.00 price objective on BioMarin Pharmaceutical and gave the company an "outperform" rating in a report on Tuesday, July 15th. Wall Street Zen lowered BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Citigroup cut their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, JPMorgan Chase & Co. boosted their target price on BioMarin Pharmaceutical from $108.00 to $113.00 and gave the company an "overweight" rating in a research report on Monday, July 14th. Six investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $93.74.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.